Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników

Znaleziono wyników: 19

Liczba wyników na stronie
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników

Wyniki wyszukiwania

Wyszukiwano:
w słowach kluczowych:  dimer lizozymu
help Sortuj według:

help Ogranicz wyniki do:
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników
The study aimed at determining the effect of a multiple dose of lysozyme dimer (Lydium-KLP Nika Health Products) on primary humoral response in SRBC - immunized mice. The effects of a single (20 µg/kg) lysozyme dimer administered 2 h prior to antigen injection were compared with those of lysozyme dimer multiple doses (two-four) administered at one week intervals. The results of the study show that lysozyme dimer, irrespective of the number and range of the doses (2, 20 or 200 µg/kg) enhances humoral response to the antigen. The adjuvant action of lysozyme dimer is expressed in the increasing number of splenocytes producing hemolytic antibodies (PFC) and the total and 2-mercaptoethanol resistant level of anti-SRBC hemagglutinins. The strongest activation of the immune response was observed after a single administration and multiple injections at doses of 2 or 20 µg/kg. Three doses of lysozyme dimer (200 µg/kg each) injected at 7-day intervals decreased the number of PFC induced by this drug administered in a single dose of 20 µg/kg 2 h prior to immunization, but maintaining the potentializing impact on anti-SRBC antibody production. The results obtained in the study indicate that multiple doses of lysozyme dimer administered in doses recommended in veterinary practice (2-20 µg/kg), at 7-day intervals do not results in immunological tolerance.
The purpose of the field trials was to establish the efficacy of the acute clinical mastitis treatment with antibiotics in connection with an i.v. injection of an immunomodulator (lysozyme dimer). The trials were conducted on 164 cows (190 sick quarters) divided into 4 groups (8 subgroups) after diagnosis was carried out and milk samples were taken. Four antibiotic products (containing: 1/ Amoxycillin + Clavulanic acid + Prednisolone, 2/ Lincomycin + Neomycin + Prednisolone, 3/ Neomycin + Penicillin G + Novobiocin + Streptomycin + Prednisolone, 4/ Penicillin + Neomycin) were given intramammary infusions at doses recommended by manufacturers with or without (control subgroups) one i.v. injection of lysozyme dimer at a dose of 10 µg/kg b.w. (experimental subgroups). Examinations checking results (clinical, bacteriological, SCC) were conducted on the 7th, 14th, and 21st days after treatment. The criteria of recovery were: regression of clinical signs in the udder, normal appearance of milk, decline of bacteria in milk, decrease of SCC. The recovery rates were 74.1% (1), 53.8% (2), 43.5% (3) and 50.0% of the quarters (4) in control subgroups versus 80.0%, 56.0%, 65.2% and 57.1% of quarters, respectively, in experimental subgroups. An average recovery of 56.3% of the quarters treated with intramammary infusions of antibiotic products and 64.9% of the quarters treated with the same antibiotics connected with the single injection of lysozyme dimer (p = 0.11). The average recovery rate among control cows was 56.1% vs. 65.8% among experimental cows (p = 0.1). The injection of the immunomodulator resulted in an increase of recoveries in acute mastitis cases caused by Str. uberis (from 28.3% to 76.9%), CNS (from 68.7% to 90.9%), E. coli (from 16.7% to 63.3%, and A. pyogenes (from 0% to 16.7%) or Staph. aureus (from 0% to 40%). In conclusion, the intramammary antibiotic products at the recommended doses are efficient enough in clinical mastitis cases caused by Str. agalactiae and CNS, poorly efficient in cases caused by E. coli and Str. uberis and not at all in cases caused by Staph. aureus and A. pyogenes. One i.v. injection of lysozyme dimer increases the efficacy of intramammary antibiotic treatment of acute forms of mastitis caused by CNS, Str. dyagalactiae, Str. uberis, E. coli, and even Staph. aureus or Arcanobacterium pyogenes.
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.